Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

Keyhani, Elahe; Muhammadnejad, Ahad; Karimlou, Masoud

doi:10.7314/apjcp.2012.13.11.5477

Cited by 14 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be a possible referral bias as our laboratory is a tertiary cancer centre. Indeed, higher rates of HER-2/neu amplification have been reported from similar centers [24,25]. An equivocal FISH result was observed in nine cases (2.08%).…”

Section: Acknowledgementsmentioning

confidence: 92%

HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study

Eswarachary

et al. 2017

JCDR

View full text Add to dashboard Cite

Introduction: The development of trastuzumab, a HER-2/ neu targeted monoclonal antibody resulted in significant improvements in clinical response and survival in HER-2/neu gene amplified group of patients. Thus, accurate assessment of HER-2/neu status becomes critical. Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are the most commonly used methods for this purpose and specific recommendations exist with regard to the concordance to be observed between the two tests.Aim: Here, we report and evaluate the concordance rate between FISH and IHC for HER-2/neu status in breast cancer specimens. Materials and Methods:Archival paraffin blocks of tumour tissue from 450 patients of breast cancer were analyzed for Her-2/neu status using FISH and IHC.Results: There was a highly significant concordance between the results of FISH and IHC assays in HER-2/neu status assessment in invasive breast cancer cases. There were inverse associations between the expression of Oestrogen Receptors/ Progesterone Receptors (ER/PR) and HER-2/neu amplification. Conclusion:Although, IHC gave significant concordant results with FISH in determining HER-2/neu status, its subjective grading system precludes its use as a gold standard. FISH should always be used to determine true gene amplification when the IHC results are equivocal.

show abstract

Section: Acknowledgementsmentioning

confidence: 92%

HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study

Eswarachary

et al. 2017

JCDR

View full text Add to dashboard Cite

show abstract

“…The most important study regarding HER-2 expression in Iranian Breast cancer was conducted by Keyhani et al [16]. In this review article 22 studies were included and 3,033 patients were evaluated, 1,350 were diagnosed as HER-2-positive by IHC.…”

Section: Discussionmentioning

confidence: 99%

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation

Mirmalek

Kani

Mehrabi

et al. 2015

ijtmgh

View full text Add to dashboard Cite

Introduction: Overexpression of Human Epidermal Growth factor Receptor-2 (HER-2) is one of the most important prognostic and predictive factors of breast cancer, observed in 25% -30% of breast carcinoma patients leading to poor prognosis and feasible anti HER-2 antibody drugs. The objective of this study was to evaluate the HER-2 frequency in target population and its correlation with histologic grade as well as tumor pathology, estrogen receptor (ER) and P53 in our patients. Methods: A total of 300 cases (all female) aged 24-80 year, were randomly selected from patients who were admitted in two of the Tehran University of Medical Sciences affiliated centers (Emam Khomeini Cancer Institute and Shariati hospital) over a 2-year period (2013)(2014). Assessment of tumors for HER-2, P53, ER, pathological type and histologic grade was performed. HER-2 over expression defined as three plus (+++) in immunohistochemistry (IHC). Results: The mean age was 49.6±11 years. HER-2 over expression was seen in 34% of the patients. Significant correlations were found between HER-2+, P53+ and high histologic grade and ER (P<0.05). However, there was no significant correlation between HER-2 and pathologic type of tumors in our study. Conclusion: Co-expression of several poor prognostic biomarkers in breast cancer (HER-2 +, P53 +, ER-, high grade) may predict more aggressive phenotype, worse disease and lower overall survival in these patients.

show abstract

“…La terapia con trastuzumab produce una mejora de la supervivencia libre de enfermedad en aproximadamente el 50% de las pacientes y en 33%, mejora la supervivencia global (8)(9) . Sin embargo, el costo elevado de este fármaco y sus potenciales efectos adversos entre los que figuran fiebre, vómitos, dolor de cabeza, fatiga, y algunos más serios a considerar, como las cardiomiopatías y la toxicidad pulmonar (10)(11) , hacen necesario determinar la expresión del HER2 para decidir el uso de esta terapia con un balance costo beneficio adecuado para las pacientes.…”

Section: Introductionunclassified

Factores clinicopatológicos asociados a la amplificación del gen HER2/neu en pacientes con cáncer de mama HER2 2+

Guevara

Aguedo

2018

An Fac med

View full text Add to dashboard Cite

Introducción. Un subgrupo de los carcinomas de mama sobreexpresa el receptor 2 del factor de crecimiento epidérmico (HER2). La determinación de esta sobreexpresión se realiza por inmunohistoquímica. La dificultad de diagnóstico surge cuando el resultado es ambiguo (2+), haciendo necesario realizar hibridación in situ (ISH) para determinar la amplificación del gen HER2/neu. Objetivo. Determinar si la amplificación del gen HER2/neu en los casos HER2 2+, se encuentra asociado a factores clinicopatologicos pronósticos. Diseño. Estudio descriptivo de corte transversal. Institución. Servicio de patología quirúrgica, Hospital Guillermo Almenara Irigoyen. Lima, Perú. Participantes. Casos de cáncer de mama HER2 2+. Metodología. Se estudiaron 117 casos de cáncer de mama HER2 2+ diagnosticados entre los años 2010 – 2015, a los que posteriormente se les realizó ISH. Todos los datos fueron analizados con el programa estadístico SPSS 22. Se utilizó el test de Chi cuadrado para analizar la asociación entre las variables. Principales medidas de resultados. Factores asociados a la amplificación del gen HER2/neu. Resultados. La amplificación del gen HER2/neu se observó en 41% del total de casos. En estos, se observó con mayor frecuencia un grado histológico III (66%), compromiso ganglionar presente (61%), tamaño tumoral ≥ 2 cm (86%) y Ki 67 ≥ 20% (83%). Se encontró una asociación estadísticamente significativa con una edad ≥ 50 años (X2 test, P=0,004) y el grado histológico III (X2 test, P=0.017). Conclusión. La amplificación del gen HER2/neu en casos ambiguos está asociado a una edad ≥ 50 años y grado histológico III.

show abstract

Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

Cited by 14 publications

References 31 publications

HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study

HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation

Factores clinicopatológicos asociados a la amplificación del gen HER2/neu en pacientes con cáncer de mama HER2 2+

Contact Info

Product

Resources

About